

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number
WO 03/014300 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number: PCT/US02/24624
- (22) International Filing Date: 2 August 2002 (02.08.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/310,362 6 August 2001 (06.08.2001) US
60/357,501 15 February 2002 (15.02.2002) US
- (71) Applicant (for all designated States except US): **EX-ELIXIS, INC.** [US/US]; P.O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **FRIEDMAN, Lori** [US/US]; One Bayside Village Place, Unit 212, San Francisco, CA 94107 (US). **PLOWMAN, Gregory, D.** [US/US]; 35 Winding Way, San Carlos, CA 94070 (US). **FRANCIS-LANG, Helen** [GB/US]; 1782 Pacific Avenue, Apt. 2, San Francisco, CA 94109 (US). **LI, Danxi** [CN/US]; 90 Behr Avenue, #302, San Francisco, CA 94131 (US). **FUNKE, Roel, P.** [NL/US]; 343 California Avenue, South San Francisco, CA 94080 (US).
- (74) Agents: **BRUNELLE, Jan** et al.; Exelixis, Inc., P. O. Box 511., 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TRPS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

(57) Abstract: Human TRP genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising for agents that modulate the activity of TRP are provided.



WO 03/014300 A2

TRPs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent applications 60/310,362
5 filed 8/6/2001, and 60/357,501 filed 2/15/2002. The contents of the prior applications are hereby incorporated in their entirety.

BACKGROUND OF THE INVENTION

The p53 gene is mutated in over 50 different types of human cancers, including
10 familial and spontaneous cancers, and is believed to be the most commonly mutated gene in human cancer (Zambetti and Levine, FASEB (1993) 7:855-865; Hollstein, *et al.*, Nucleic Acids Res. (1994) 22:3551-3555). Greater than 90% of mutations in the p53 gene are missense mutations that alter a single amino acid that inactivates p53 function. Aberrant forms of human p53 are associated with poor prognosis, more aggressive tumors,
15 metastasis, and short survival rates (Mitsudomi *et al.*, Clin Cancer Res 2000 Oct; 6(10):4055-63; Koshland, Science (1993) 262:1953).

The human p53 protein normally functions as a central integrator of signals including DNA damage, hypoxia, nucleotide deprivation, and oncogene activation (Prives, Cell (1998) 95:5-8). In response to these signals, p53 protein levels are greatly increased with
20 the result that the accumulated p53 activates cell cycle arrest or apoptosis depending on the nature and strength of these signals. Indeed, multiple lines of experimental evidence have pointed to a key role for p53 as a tumor suppressor (Levine, Cell (1997) 88:323-331). For example, homozygous p53 "knockout" mice are developmentally normal but exhibit nearly 100% incidence of neoplasia in the first year of life (Donehower *et al.*, Nature
25 (1992) 356:215-221).

The biochemical mechanisms and pathways through which p53 functions in normal and cancerous cells are not fully understood, but one clearly important aspect of p53 function is its activity as a gene-specific transcriptional activator. Among the genes with known p53-response elements are several with well-characterized roles in either regulation
30 of the cell cycle or apoptosis, including GADD45, p21/Waf1/Cip1, cyclin G, Bax, IGF-BP3, and MDM2 (Levine, Cell (1997) 88:323-331).

Morphogenesis and cell differentiation in multicellular organisms often require accurate control of cell divisions. The *tribbles* gene of *Drosophila* is a novel cell cycle regulator that plays a critical role in cell division control during *Drosophila* development.

Tribbles acts by specifically inducing degradation of the CDC25 mitotic activators, *string* and *twine*, via the proteosome pathway. By regulating CDC25, *tribbles* serves to coordinate entry into mitosis with morphogenesis and cell fate determination (Grosshans J, Wieschaus E., Cell 2000 May 26;101(5):523-31; Mata J et al., Cell 2000 May 26;101(5):511-22; Seher TC, Leptin M., Curr Biol 2000 Jun 1;10(11):623-9).

The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as p53, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

All references cited herein, including sequence information in referenced Genbank identifier numbers and website references, are incorporated herein in their entireties.

SUMMARY OF THE INVENTION

We have discovered genes that modify the p53 pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as TRP. The invention provides methods for utilizing these p53 modifier genes and polypeptides to identify TRP-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired p53 function and/or TRP function. Preferred TRP-

modulating agents specifically bind to TRP polypeptides and restore p53 function. Other preferred TRP-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress TRP gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

5 TRP modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with a TRP polypeptide or nucleic acid. In one embodiment, candidate TRP modulating agents are tested with an assay system comprising a TRP polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate p53 modulating agents. The assay
10 system may be cell-based or cell-free. TRP-modulating agents include TRP related proteins (e.g. dominant negative mutants, and biotherapeutics); TRP-specific antibodies; TRP-specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with TRP or compete with TRP binding partner (e.g. by binding to a TRP binding partner). In one specific embodiment, a small molecule
15 modulator is identified using a kinase assay. In specific embodiments, the screening assay system is selected from a binding assay, an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

In another embodiment, candidate p53 pathway modulating agents are further tested using a second assay system that detects changes in the p53 pathway, such as angiogenic,
20 apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the p53 pathway, such as an angiogenic, apoptotic, or cell
25 proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the TRP function and/or the p53 pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a TRP polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a
30 mammalian animal predetermined to have a pathology associated the p53 pathway.

DETAILED DESCRIPTION OF THE INVENTION

Genetic screens were designed to identify modifiers of the p53 pathway in *Drosophila*, where a genetic modifier screen was carried out in which p53 was overexpressed in the

wing (Ollmann M, et al., Cell 2000 101: 91-101). The tribbles (CG5408) gene was identified as a modifier of the p53 pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, Tribbles related (TRP) genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies

5 associated with a defective p53 signaling pathway, such as cancer.

In vitro and in vivo methods of assessing TRP function are provided herein.

Modulation of the TRP or their respective binding partners is useful for understanding the association of the p53 pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for p53 related pathologies. TRP-
10 modulating agents that act by inhibiting or enhancing TRP expression, directly or indirectly, for example, by affecting a TRP function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. TRP modulating agents are useful in diagnosis, therapy and pharmaceutical development.

15 **Nucleic acids and polypeptides of the invention**

Sequences related to TRP nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) number) as GI#s 11056039 (SEQ ID NO:1), 13399327 (SEQ ID NO:3), 1507671 (SEQ ID NO:5), and 11056053 (SEQ ID NO:6) for nucleic acid, and GI#s 11056040 (SEQ ID NO:8),
20 13399328 (SEQ ID NO:9), and 1507672 (SEQ ID NO:10) for polypeptides. Additionally, sequences of clones N7_2_C05 (SEQ ID NO:2), N24B07 (SEQ ID NO:4), and N7_2_A01 (SEQ ID NO:7) can also be used in the methods of the invention.

TRPs are kinase proteins with kinase domains. The term "TRP polypeptide" refers to a full-length TRP protein or a functionally active fragment or derivative thereof. A
25 "functionally active" TRP fragment or derivative exhibits one or more functional activities associated with a full-length, wild-type TRP protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of TRP proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*,
30 eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of a TRP, such as a kinase domain or a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). For example, the kinase domains of TRPs from GI#

s11056040, 13399328, and 1507672 (SEQ ID NOs:8, 9, and 10, respectively) are located respectively at approximately amino acid residues 71 to 315, 104 to 338, and 64 to 308 (PFAM 00069). Methods for obtaining TRP polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-
5 containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of any one of SEQ ID NOs:8, 9, or 10 (a TRP). In further preferred embodiments, the fragment comprises the entire kinase (functionally active) domain.

The term "TRP nucleic acid" refers to a DNA or RNA molecule that encodes a TRP
10 polypeptide. Preferably, the TRP polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with TRP. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3-
15 dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA *et al.*, Genome Research (2000)
20 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species
25 generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as *Drosophila*, may correspond to multiple genes (paralogs) in another, such as
30 human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps,

if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, Advances in Applied Mathematics 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, J. of Molec.Biol., 147:195-197; Nicholas *et al.*, 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, Genomics 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 Nucl. Acids Res. 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of any of SEQ ID NOs:1, 2, 3, 4, 5,

6, or 7. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*, Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers
5 (1994); Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of any one of SEQ ID NOs:1, 2, 3, 4, 5, 6, or 7 under stringent hybridization conditions that comprise: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising
10 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.2X SSC and 0.1% SDS (sodium dodecyl
15 sulfate).

In other embodiments, moderately stringent hybridization conditions are used that comprise: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA; hybridization for
20 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

Alternatively, low stringency conditions can be used that comprise: incubation for 8
25 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

30 **Isolation, Production, Expression, and Mis-expression of TRP Nucleic Acids and Polypeptides**

TRP nucleic acids and polypeptides, useful for identifying and testing agents that modulate TRP function and for other applications related to the involvement of TRP in the p53 pathway. TRP nucleic acids and derivatives and orthologs thereof may be obtained

using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance,

5 production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of a TRP protein for

10 assays used to assess TRP function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (*e.g.*, Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New

15 York 1999; Stanbury PF et al., *Principles of Fermentation Technology*, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) *Protein Purification Protocols*, Humana Press, New Jersey, 1996; Coligan JE et al, *Current Protocols in Protein Science* (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant TRP is expressed in a cell line known to have defective p53 function (*e.g.* SAOS-2

20 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29 and DLD-1 colon cancer cells, among others, available from American Type Culture Collection (ATCC), Manassas, VA). The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

The nucleotide sequence encoding a TRP polypeptide can be inserted into any

25 appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native TRP gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus);

30 microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. A host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the TRP gene product, the expression vector can comprise a promoter operably linked to a TRP gene nucleic acid, one or more origins of replication,

and, one or more selectable markers (e.g. thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the TRP gene product based on the physical or functional properties of the TRP protein in *in vitro* assay systems (e.g. immunoassays).

5 The TRP protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the
10 chimeric product. A chimeric product may also be made by protein synthetic techniques, e.g. by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

 Once a recombinant cell that expresses the TRP gene sequence is identified, the gene product can be isolated and purified using standard methods (e.g. ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis).
15 Alternatively, native TRP proteins can be purified from natural sources, by standard methods (e.g. immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

 The methods of this invention may also use cells that have been engineered for altered
20 expression (mis-expression) of TRP or other genes associated with the p53 pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (e.g. by gene knock-out or blocking expression that would otherwise normally occur).

25 Genetically modified animals

 Animal models that have been genetically modified to alter TRP expression may be used in *in vivo* assays to test for activity of a candidate p53 modulating agent, or to further assess the role of TRP in a p53 pathway process such as apoptosis or cell proliferation. Preferably, the altered TRP expression results in a detectable phenotype, such as decreased
30 or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal TRP expression. The genetically modified animal may additionally have altered p53 expression (e.g. p53 knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice), cows, horses, goats, sheep, pigs, dogs and cats. Preferred non-mammalian species include zebrafish, *C.*

elegans, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sanford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer *et al.*, Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous TRP gene that results in a decrease of TRP function, preferably such that TRP expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse TRP gene is used to construct a

homologous recombination vector suitable for altering an endogenous TRP gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner *et al.*, Nature (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, Science (1989) 244:1281-1288; Simms *et al.*, Bio/Technology (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH *et al.*, (1994) Scan J Immunol 40:257-264; Declerck PJ *et al.*, (1995) J Biol Chem. 270:8397-400).

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the TRP gene, e.g., by introduction of additional copies of TRP, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the TRP gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X *et al.* (2000) Nat Genet 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the p53 pathway, as animal models of disease and disorders implicating defective p53 function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in

screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered TRP function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered TRP expression that receive candidate therapeutic agent.

In addition to the above-described genetically modified animals having altered TRP function, animal models having defective p53 function (and otherwise normal TRP function), can be used in the methods of the present invention. For example, a p53 knockout mouse can be used to assess, *in vivo*, the activity of a candidate p53 modulating agent identified in one of the *in vitro* assays described below. p53 knockout mice are described in the literature (Jacks et al., Nature 2001;410:1111-1116, 1043-1044; Donehower *et al.*, supra). Preferably, the candidate p53 modulating agent when administered to a model system with cells defective in p53 function, produces a detectable phenotypic change in the model system indicating that the p53 function is restored, i.e., the cells exhibit normal cell cycle progression.

Modulating Agents

The invention provides methods to identify agents that interact with and/or modulate the function of TRP and/or the p53 pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the p53 pathway, as well as in further analysis of the TRP protein and its contribution to the p53 pathway. Accordingly, the invention also provides methods for modulating the p53 pathway comprising the step of specifically modulating TRP activity by administering a TRP-interacting or -modulating agent.

As used herein, an "TRP-modulating agent" is any agent that modulated TRP function, for example, an agent that interacts with TRP to inhibit or enhance TRP activity or otherwise affect normal TRP function. TRP function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a preferred embodiment, the TRP - modulating agent specifically modulates the function of the TRP. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the TRP polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the TRP. These phrases also encompasses modulating agents that alter the interaction of the TRP with a binding partner, substrate, or cofactor (e.g. by binding to a

binding partner of a TRP, or to a protein/binding partner complex, and altering TRP function). In a further preferred embodiment, the TRP- modulating agent is a modulator of the p53 pathway (e.g. it restores and/or upregulates p53 function) and thus is also a p53- modulating agent.

- 5 Preferred TRP-modulating agents include small molecule compounds; TRP-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients.
- 10 Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19th edition.

Small molecule modulators

- Small molecules, are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in
- 15 the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical
- 20 libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the TRP protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for TRP-modulating activity. Methods for
- 25 generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

- Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating
- 30 pathologies associated with the p53 pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may

be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

5 Specific TRP-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the p53 pathway and related disorders, as well as in validation assays for other TRP-modulating agents. In a preferred embodiment, TRP-interacting proteins affect normal TRP function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, TRP-
10 interacting proteins are useful in detecting and providing information about the function of TRP proteins, as is relevant to p53 related disorders, such as cancer (e.g., for diagnostic means).

 A TRP-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with a TRP, such as a member of the TRP pathway that
15 modulates TRP expression, localization, and/or activity. TRP-modulators include dominant negative forms of TRP-interacting proteins and of TRP proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous TRP-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford,
20 England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).

25 An TRP-interacting protein may be an exogenous protein, such as a TRP-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). TRP antibodies are further discussed below.

30 In preferred embodiments, a TRP-interacting protein specifically binds a TRP protein. In alternative preferred embodiments, a TRP-modulating agent binds a TRP substrate, binding partner, or cofactor.

Antibodies

In another embodiment, the protein modulator is a TRP specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify TRP modulators. The antibodies can also be used in
5 dissecting the portions of the TRP pathway responsible for various cellular responses and in the general processing and maturation of the TRP.

Antibodies that specifically bind TRP polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of TRP polypeptide, and more preferably, to human TRP. Antibodies may be polyclonal,
10 monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of TRP which are particularly antigenic can be selected, for example, by routine screening of TRP polypeptides for antigenicity or by applying a theoretical method for
15 selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Natl. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence shown in any of SEQ ID NOs:8, 9, or 10. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger can be made by standard procedures as described (Harlow and Lane, *supra*;
20 Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of TRP or substantially purified fragments thereof. If TRP fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of a TRP protein. In a particular embodiment, TRP-specific
25 antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.
30 The presence of TRP-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding TRP polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

Chimeric antibodies specific to TRP polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

TRP-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide

metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their
5 targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies.
10 Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose
15 solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml.
20 Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Nucleic Acid Modulators

Other preferred TRP-modulating agents comprise nucleic acid molecules, such as
25 antisense oligomers or double stranded RNA (dsRNA), which generally inhibit TRP activity. Preferred nucleic acid modulators interfere with the function of the TRP nucleic acid such as DNA replication, transcription, translocation of the TRP RNA to the site of protein translation, translation of protein from the TRP RNA, splicing of the TRP RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or
30 facilitated by the TRP RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to a TRP mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. TRP-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is

preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

Alternative preferred TRP nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498).

Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the

treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, *et al*, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36:1923-1937; Tonkinson JL *et al.*, Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65).

- 5 Accordingly, in one aspect of the invention, a TRP-specific nucleic acid modulator is used in an assay to further elucidate the role of the TRP in the p53 pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, a TRP-specific antisense oligomer is used as a therapeutic agent for treatment of p53-related disease states.

10

Assay Systems

- The invention provides assay systems and screening methods for identifying specific modulators of TRP activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or
- 15 measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the TRP nucleic acid or protein. In general, secondary assays further assess the activity of a TRP modulating agent identified by a primary assay and may confirm that the modulating agent affects TRP in a manner relevant to the p53 pathway. In some cases, TRP modulators will be
- 20 directly tested in a secondary assay.

- In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising a TRP polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. kinase activity), which is based on the particular molecular event the
- 25 screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates TRP activity, and hence the p53 pathway. The TRP polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

Primary Assays

- 30 The type of modulator tested generally determines the type of primary assay.

Primary assays for small molecule modulators

For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in
5 Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude
10 cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (*e.g.*, receptor-ligand binding), transcriptional activity (*e.g.*, using a reporter gene), enzymatic activity (*e.g.*, via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide
15 range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

Cell-based screening assays usually require systems for recombinant expression of TRP and any auxiliary proteins demanded by the particular assay. Appropriate methods
20 for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when TRP-interacting proteins are used in
25 screens to identify small molecule modulators, the binding specificity of the interacting protein to the TRP protein may be assayed by various known methods such as substrate processing (*e.g.* ability of the candidate TRP-specific binding agents to function as negative effectors in TRP-expressing cells), binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}),
30 and immunogenicity (*e.g.* ability to elicit TRP specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a TRP polypeptide, a fusion protein thereof, or to cells or membranes

bearing the polypeptide or fusion protein. The TRP polypeptide can be full length or a fragment thereof that retains functional TRP activity. The TRP polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The TRP polypeptide is preferably human TRP, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of TRP interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has TRP-specific binding activity, and can be used to assess normal TRP gene function.

Suitable assay formats that may be adapted to screen for TRP modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr Opin Biotechnol 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (*e.g.*, Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451).

A variety of suitable assay systems may be used to identify candidate TRP and p53 pathway modulators (*e.g.* U.S. Pat. No. 6,165,992 (kinase assays); U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); U.S. Pat. No. 6,020,135 (p53 modulation), among others). Specific preferred assays are described in more detail below.

Kinase assays. In some preferred embodiments the screening assay detects the ability of the test agent to modulate the kinase activity of a TRP polypeptide. In further embodiments, a cell-free kinase assay system is used to identify a candidate p53 modulating agent, and a secondary, cell-based assay, such as an apoptosis or hypoxic induction assay (described below), may be used to further characterize the candidate p53 modulating agent. Many different assays for kinases have been reported in the literature and are well known to those skilled in the art (*e.g.* U.S. Pat. No. 6,165,992; Zhu et al., Nature Genetics (2000) 26:283-289; and WO0073469). Radioassays, which monitor the transfer of a gamma phosphate are frequently used. For instance, a scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma phosphate from gamma -³³P

ATP to a biotinylated peptide substrate; the substrate is captured on a streptavidin coated bead that transmits the signal (Beveridge M *et al.*, J Biomol Screen (2000) 5:205-212).

This assay uses the scintillation proximity assay (SPA), in which only radio-ligand bound to receptors tethered to the surface of an SPA bead are detected by the scintillant

5 immobilized within it, allowing binding to be measured without separation of bound from free ligand.

Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates. For instance, the kinase receptor activation (KIRA) assay

measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in

10 cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, Dev Biol Stand (1999) 97:121-133).

Another example of antibody based assays for protein kinase activity is TRF (time-resolved fluorometry). This method utilizes europium chelate-labeled anti-

15 phosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using time-resolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., Anal Biochem 1996 Jul 1;238(2):159-64).

20 **Apoptosis assays.** Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara *et al.*, 1989, J. Exp. Med. 169, 1747). Apoptosis may further

25 be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). An apoptosis assay system may comprise a cell that expresses a TRP, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify

30 candidate p53 modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether TRP function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express TRP relative to wild type

example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express TRP relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the TRP plays a direct role in cell proliferation or cell cycle.

5

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses a TRP, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether TRP function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express TRP relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the TRP plays a direct role in angiogenesis.

25

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glycolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with TRP in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses a TRP, and that

30

optionally has a mutated p53 (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether TRP function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express TRP relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the TRP plays a direct role in hypoxic induction.

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators

cells. Differences in apoptotic response compared to wild type cells suggests that the TRP plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

5 **Cell proliferation and cell cycle assays.** Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, Int. J. Cancer 38, 369; Campana *et al.*, 1988, J. Immunol. Meth. 107, 79), or by
10 other means.

Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA.
15 Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter).

Cell proliferation may also be assayed by colony formation in soft agar (Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with
20 TRP are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW *et al.* (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55). Cells transfected with a TRP may be stained with propidium iodide and evaluated in a flow cytometer (available
25 from Becton Dickinson).

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses a TRP, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no
30 test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system such as a cell-free kinase assay system. A cell proliferation assay may also be used to test whether TRP function plays a direct role in cell proliferation or cell cycle. For

example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express TRP relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the TRP plays a direct role in cell proliferation or cell cycle.

5

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses a TRP, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether TRP function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express TRP relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the TRP plays a direct role in angiogenesis.

25

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glycolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with TRP in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses a TRP, and that

30

optionally has a mutated p53 (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether TRP function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express TRP relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the TRP plays a direct role in hypoxic induction.

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators

against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

5 **Cell Migration.** An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, J Biol Chem 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell
10 size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but
15 longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS
20 FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing a TRP's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

25 **Sprouting assay.** A sprouting assay is a three-dimensional *in vitro* angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the
30 extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998).

Spheroids are harvested and seeded in 900 μ l of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100 μ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

Primary assays for antibody modulators

For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the TRP protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting TRP-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

Primary assays for nucleic acid modulators

For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance TRP gene expression, preferably mRNA expression. In general, expression analysis comprises comparing TRP expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express TRP) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that TRP mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the TRP protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

Secondary Assays

Secondary assays may be used to further assess the activity of TRP-modulating agent identified by any of the above methods to confirm that the modulating agent affects TRP in a manner relevant to the p53 pathway. As used herein, TRP-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with TRP.

Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express TRP) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate TRP-modulating agent results in changes in the p53 pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use “sensitized genetic backgrounds”, which, as used herein, describe cells or animals engineered for altered expression of genes in the p53 or interacting pathways.

Cell-based assays

Cell based assays may use a variety of mammalian cell lines known to have defective p53 function (*e.g.* SAOS-2 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29 and DLD-1 colon cancer cells, among others, available from American Type Culture Collection (ATCC), Manassas, VA). Cell based assays may detect endogenous p53 pathway activity or may rely on recombinant expression of p53 pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

Animal Assays

A variety of non-human animal models of normal or defective p53 pathway may be used to test candidate TRP modulators. Models for defective p53 pathway typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the p53 pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, p53 pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal p53 are used to test the candidate modulator's affect on TRP in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen
5 IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the TRP. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets
10 may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

In another preferred embodiment, the effect of the candidate modulator on TRP is
15 assessed via tumorigenicity assays. In one example, xenograft human tumors are implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the TRP endogenously are injected in the flank, 1×10^5 to 1×10^7 cells per mouse in a volume of 100 μ L using a 27gauge needle. Mice are then ear tagged and tumors are measured twice
20 weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the
25 measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

30

Diagnostic and therapeutic uses

Specific TRP-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the p53 pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention

also provides methods for modulating the p53 pathway in a cell, preferably a cell pre-determined to have defective or impaired p53 function (e.g. due to overexpression, underexpression, or misexpression of p53, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates TRP activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the p53 function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored p53 function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired p53 function by administering a therapeutically effective amount of a TRP -modulating agent that modulates the p53 pathway. The invention further provides methods for modulating TRP function in a cell, preferably a cell pre-determined to have defective or impaired TRP function, by administering a TRP -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired TRP function by administering a therapeutically effective amount of a TRP -modulating agent.

The discovery that TRP is implicated in p53 pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the p53 pathway and for the identification of subjects having a predisposition to such diseases and disorders.

Various expression analysis methods can be used to diagnose whether TRP expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective p53 signaling that express a TRP, are identified as amenable to treatment with a TRP modulating agent. In a preferred application, the p53 defective tissue overexpresses a TRP relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial TRP cDNA sequences as probes, can determine whether particular tumors express or overexpress TRP. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis

of TRP expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

Various other diagnostic methods may be performed, for example, utilizing reagents such as the TRP oligonucleotides, and antibodies directed against a TRP, as described above for: (1) the detection of the presence of TRP gene mutations, or the detection of either over- or under-expression of TRP mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of TRP gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by TRP.

Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in TRP expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for TRP expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer, most preferably a cancer as shown in TABLE 1. The probe may be either DNA or protein, including an antibody.

EXAMPLES

The following experimental section and examples are offered by way of illustration and not by way of limitation.

I. Drosophila p53 screen

The *Drosophila* p53 gene was overexpressed specifically in the wing using the vestigial margin quadrant enhancer. Increasing quantities of *Drosophila* p53 (titrated using different strength transgenic inserts in 1 or 2 copies) caused deterioration of normal wing morphology from mild to strong, with phenotypes including disruption of pattern and polarity of wing hairs, shortening and thickening of wing veins, progressive crumpling of the wing and appearance of dark "death" inclusions in wing blade. In a screen designed to identify enhancers and suppressors of *Drosophila* p53, homozygous females carrying two copies of p53 were crossed to 5663 males carrying random insertions of a piggyBac transposon (Fraser *et al.*, Virology (1985) 145:356-361). Progeny containing insertions were compared to non-insertion-bearing sibling progeny for enhancement or suppression of the p53 phenotypes. Sequence information surrounding the piggyBac insertion site was used to identify the modifier genes. Modifiers of the wing phenotype were identified as

members of the p53 pathway. tribbles (CG5408) was a suppressor of the wing phenotype. Human orthologs of the modifiers are referred to herein as TRP.

BLAST analysis (Altschul et al., *supra*) was employed to identify Targets from *Drosophila* modifiers. For example, representative sequences from TRP, GI#s 11056040, 13399328, and 1507672 (SEQ ID NOs:8, 9, and 10, respectively), share 45%, 50%, and 49% amino acid identity, respectively, with the *Drosophila* tribbles (CG5408).

Various domains, signals, and functional subunits in proteins were analyzed using the PSORT (Nakai K., and Horton P., Trends Biochem Sci, 1999, 24:34-6; Kenta Nakai, Protein sorting signals and prediction of subcellular localization, Adv. Protein Chem. 54, 277-344 (2000)), PFAM (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2), SMART (Ponting CP, et al., SMART: identification and annotation of domains from signaling and extracellular protein sequences. Nucleic Acids Res. 1999 Jan 1;27(1):229-32), TM-HMM (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998), and clust (Remm M, and Sonnhammer E. Classification of transmembrane protein families in the *Caenorhabditis elegans* genome and identification of human orthologs. Genome Res. 2000 Nov;10(11):1679-89) programs. For example, the kinase domains of TRPs from GI# s11056040, 13399328, and 1507672 (SEQ ID NOs:8, 9, and 10, respectively) are located respectively at approximately amino acid residues 71 to 315, 104 to 338, and 64 to 308 (PFAM 00069).

II. High-Throughput In Vitro Fluorescence Polarization Assay

Fluorescently-labeled TRP peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of TRP activity.

III. High-Throughput In Vitro Binding Assay.

³³P-labeled TRP peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml

BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-
avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then
added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS,
and counted in a scintillation counter. Test agents that cause a difference in activity
5 relative to control without test agent are identified as candidate p53 modulating agents.

IV. Immunoprecipitations and Immunoblotting

For coprecipitation of transfected proteins, 3×10^6 appropriate recombinant cells
containing the TRP proteins are plated on 10-cm dishes and transfected on the following
10 day with expression constructs. The total amount of DNA is kept constant in each
transfection by adding empty vector. After 24 h, cells are collected, washed once with
phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50
mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium
orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors
15 (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is
removed by centrifugation twice at $15,000 \times g$ for 15 min. The cell lysate is incubated
with 25 μ l of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

After extensive washing with lysis buffer, proteins bound to the beads are solubilized
by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis,
20 transferred to polyvinylidene difluoride membrane and blotted with the indicated
antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the
appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western
blotting detection system (Amersham Pharmacia Biotech).

25 V. Kinase assay

A purified or partially purified TRP is diluted in a suitable reaction buffer, e.g., 50 mM
Hepes, pH 7.5, containing magnesium chloride or manganese chloride (1-20 mM) and a
peptide or polypeptide substrate, such as myelin basic protein or casein (1-10 μ g/ml). The
final concentration of the kinase is 1-20 nM. The enzyme reaction is conducted in
30 microtiter plates to facilitate optimization of reaction conditions by increasing assay
throughput. A 96-well microtiter plate is employed using a final volume 30-100 μ l. The
reaction is initiated by the addition of ^{33}P -gamma-ATP (0.5 μ Ci/ml) and incubated for 0.5
to 3 hours at room temperature. Negative controls are provided by the addition of EDTA,
which chelates the divalent cation (Mg^{2+} or Mn^{2+}) required for enzymatic activity.

Following the incubation, the enzyme reaction is quenched using EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate (MultiScreen, Millipore). The filters are subsequently washed with phosphate-buffered saline, dilute phosphoric acid (0.5%) or other suitable medium to remove excess radiolabeled ATP. Scintillation cocktail is added to the filter plate and the incorporated radioactivity is quantitated by scintillation counting (Wallac/Perkin Elmer). Activity is defined by the amount of radioactivity detected following subtraction of the negative control reaction value (EDTA quench).

10 VI. Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, Stratagene, and Ambion.

15 TaqMan analysis was used to assess expression levels of the disclosed genes in various samples.

RNA was extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/μl. Single stranded cDNA was then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

Primers for expression analysis using TaqMan assay (Applied Biosystems, Foster City, CA) were prepared according to the TaqMan protocols, and the following criteria: a) primer pairs were designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product.

Taqman reactions were carried out following manufacturer's protocols, in 25 μl total volume for 96-well plates and 10 μl total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis was prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data were normalized using 18S rRNA (universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples were compared with matched normal tissues from the same patient. A gene was considered overexpressed in a tumor

when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue was not available, a universal pool of cDNA samples was used instead. In these cases, a gene was considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., $\text{Tumor} - \text{average}(\text{all normal samples}) > 2 \times \text{STDEV}(\text{all normal samples})$).

Results are shown in Table 1. Data presented in bold indicate that greater than 50% of tested tumor samples of the tissue type indicated in row 1 exhibited over expression of the gene listed in column 1, relative to normal samples. Underlined data indicates that between 25% to 49% of tested tumor samples exhibited over expression. A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

Table1

SEQ ID NO	NA_GI#	breast		colon		lung		ovary	
1	11056039	7	11	5	30	3	14	1	7
3	13399327	2	11	<u>7</u>	<u>25</u>	0	11	0	3
6	11056053	1	11	3	25	2	11	<u>1</u>	<u>3</u>

WHAT IS CLAIMED IS:

1. A method of identifying a candidate p53 pathway modulating agent, said method comprising the steps of:
 - 5 (a) providing an assay system comprising a purified TRP polypeptide or nucleic acid or a functionally active fragment or derivative thereof;
 - (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
 - (c) detecting a test agent-biased activity of the assay system, wherein a difference
10 between the test agent-biased activity and the reference activity identifies the test agent as a candidate p53 pathway modulating agent.
2. The method of Claim 1 wherein the assay system comprises cultured cells that express the TRP polypeptide.
15
3. The method of Claim 2 wherein the cultured cells additionally have defective p53 function.
4. The method of Claim 1 wherein the assay system includes a screening assay
20 comprising a TRP polypeptide, and the candidate test agent is a small molecule modulator.
5. The method of Claim 4 wherein the assay is a kinase assay.
6. The method of Claim 1 wherein the assay system is selected from the group
25 consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
7. The method of Claim 1 wherein the assay system includes a binding assay comprising a TRP polypeptide and the candidate test agent is an antibody.
30
8. The method of Claim 1 wherein the assay system includes an expression assay comprising a TRP nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.
10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.
- 5 11. The method of Claim 1 additionally comprising:
(d) administering the candidate p53 pathway modulating agent identified in (c) to a model system comprising cells defective in p53 function and, detecting a phenotypic change in the model system that indicates that the p53 function is restored.
- 10 12. The method of Claim 11 wherein the model system is a mouse model with defective p53 function.
13. A method for modulating a p53 pathway of a cell comprising contacting a cell
15 defective in p53 function with a candidate modulator that specifically binds to a TRP polypeptide comprising an amino acid sequence selected from group consisting of SEQ ID NOs: 8, 9, and 10, whereby p53 function is restored.
14. The method of claim 13 wherein the candidate modulator is administered to a
20 vertebrate animal predetermined to have a disease or disorder resulting from a defect in p53 function.
15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.
- 25 16. The method of Claim 1, comprising the additional steps of:
(d) providing a secondary assay system comprising cultured cells or a non-human animal expressing TRP ,
(e) contacting the secondary assay system with the test agent of (b) or an agent
30 derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and
(f) detecting an agent-biased activity of the second assay system,

wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate p53 pathway modulating agent,

and wherein the second assay detects an agent-biased change in the p53 pathway.

5

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-
10 human animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a p53 pathway gene.

15 20. A method of modulating p53 pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a TRP polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the p53 pathway.

20

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:

25

- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with a probe for TRP expression;
- (c) comparing results from step (b) with a control;
- (d) determining whether step (c) indicates a likelihood of disease.

30 24. The method of claim 23 wherein said disease is cancer.

25. The method according to claim 24, wherein said cancer is a cancer as shown in Table 1 as having >25% expression level.

SEQUENCE LISTING

<110> EXELIXIS, INC.

<120> TRPs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

<130> EX02-105C-PC

<150> US 60/310,362

<151> 2001-08-06

<150> US60/357,501

<151> 2002-02-15

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 2257

<212> DNA

<213> Homo sapiens

<400> 1

```

gtgcatcccc gggcccagg gcatcagacg ggggctgatt agctccgggt tgcatacccc      60
ggaccggggg attagctccg gtttgcatac cccggaccgg gggccgggcg cgcacgagac      120
tcgcagcgga agtggaggcg gctccgcgcg cgtccgctgc taggaccgga gcagggtggt      180
agctgggctg ggatcccgag ctccggcagc ggcgcagcgg ccggcccacc tgctggtgcc      240
ctggagggtc tgagccccgg cggcgcccgg gccacgcgg aacgacgggg cgagatgcga      300
gccaccctc tagctgtctc tgcgggttcc ctgtccagga agaagcggtt ggagttggat      360
gacaacttag ataccgagcg tcccgtccag aaacgagctc gaagtgggga ccagcccaga      420
ctgccccctt gcctgttgcc cctgagccca cctactgtc cagatcgtgc aactgctgtg      480
gccactgcct ccctgtttgg gccctatgtc ctctggagc ccgaggaggg cgggcggggc      540
taccaggccc tgactgccc tacaggcact gagtatacct gcaagggtga ccccgctccg      600
gaagccccgg ccgtgttgga gccctatgcg cgggtgcccc cgcacaagca tgtgggtcgg      660
cccactgagg tcctgggtgg taccagctc ctctacgct ttttactcg gacccatggg      720
gacatgcaca gcctggtgcg aagccgccac cgtatccctg agcctgaggc tgccgtgtc      780
ttccgccaga tggccaccgc cctggcgcac tgtcaccagc acggtctggt cctgcgtgat      840
ctcaagctgt gtcgctttgt cttcgctgac cgtgagagga agaagctggt gctggagaac      900
ctggaggact cctgcgtgct gactgggcca gatgattccc tgtgggacaa gcacgcgtgc      960
ccagcctacg tgggacctga gatactcagc tcacgggcct catactcggg caaggcagcc     1020
gatgtctgga gcctgggcgt ggcgctcttc accatgctgg ccggccacta ccccttccag     1080
gactcggagc ctgtcctgct cttcggcaag atccgcgcg gggcctacgc cttgctgca     1140

```

```

ggcctctcgg ccctgcccg ctgtctggtt cgctgectcc ttcgtcggga gccagctgaa 1200
cggctcacag ccacaggcat cctcctgcac ccctggctgc gacaggacc gatgccctta 1260
gccccaaacc gatcccatct ctgggaggct gcccagggtg tccctgatgg tctggggctg 1320
gacgaagcca gggaaagagga gggagacaga gaagtgggtc tgtatggcta ggaccaccct 1380
actacacgct cagctgccaa cagtggattg agtttggggg tagctccaag ctttctcctg 1440
cctctgaact gagccaaacc ttcagtgcct tccagaaggg agaaaggcag aagcctgtgt 1500
ggagtgtgct gtgtacacat ctgctttgtt ccacacacat gcagttcctg cttgggtgct 1560
tatcagggtgc caagccctgt tctcgggtgct gggagtacag cagttagcaa aggagacaat 1620
attccctgct cacagagatg acaaactggc atccttgagc tgacaacact tttccatgac 1680
cataggtcac tgtctacact gggtagactt tgtaccagtg tcggcctcca ctgatgctgg 1740
tgctcaggca cctctgtcca aggacaatcc ctttcacaaa caaacagct gcctttgtat 1800
cttgtagctt ttcagagaaa gggaggtatc cctgtgccaa aggtccagg cctctcccct 1860
gcaactcagg acccaagccc agctcactct gggaactgtg tcccagcat ctctgtcctc 1920
ttgattaaga gattctcctt ccaggcctaa gcctgggatt tgggccagag ataagaatcc 1980
aaactatgag gctagtctt gtctaactca agactgttct ggaatgaggg tccaggcctg 2040
tcaaccatgg ggcttctgac ctgagcacca aggttgaggg acaggattag gcagggtctg 2100
tcctgtggcc acctggaaag tcccagggtg gactcttctg gggacacttg ggtccacaa 2160
tcccagggtc atactctagg ttttgatac catgagtatg tatgtttacc tgtgcctaata 2220
aaaggagaat tatgaaataa aaaaaaaaaa aaaaaaa 2257

```

```

<210> 2
<211> 1081
<212> DNA
<213> Homo sapiens

```

```

<400> 2
agatgcgagc caccctcta gctgctcctg cgggttcctt gtccaggaag aagcgggttg 60
agttggatga caacttagat accgagcgtc ccgtccagaa acgagctcga agtgggcccc 120
agcccagact gccccctgc ctgttgcccc tgagcccacc tactgctcca gatcgtgcaa 180
ctgctgtggc cactgctcc cgtcttgggc cctatgtcct cctggagccc gaggagggcg 240
ggcgggccta ccaggccctg cactgcccta caggcactga gtatacctgc aaggtgtacc 300
ccgtccagga agccctggcc gtgctggagc cctatgcgcg gctgcccccg cacaagcatg 360
tggctcggcc cactgaggtc ctggctggta ccagctcct ctacgccttt ttactcggga 420
cccatgggga catgcacagc ctggtgcgaa gccgccaccg tatccctgag cctgaggctg 480
ccgtgctctt ccgccagatg gccaccgccc tggcgccactg tcaccagcac ggtctggtcc 540

```

```

tgcgtgatct caagctgtgt cgctttgtct tcgctgaccg tgagaggaag aagctgggtgc 600
tggagaacct ggaggactcc tgcgtgctga ctgggccaga tgattccctg tgggacaagc 660
acgcgtgccc agcctacgtg ggacctgaga tactcagctc acgggcctca tactcgggca 720
aggcagccga tgtctggagc ctgggcgtgg cgctcttcac catgctggcc ggccactacc 780
ccttcacagga ctcggagcct gtctgtctct tcggcaagat ccgccgcggg gcctacgcct 840
tgcttcagag cctctcggcc cctgcccgtc gtctggttcg ctgcctcctt cgtcgggagc 900
cagctgaacg gctcacagcc acaggcatcc tctgcacccc ctggctgcga caggaccgca 960
tgcccttagc cccaaccgca tcccatctct gggaggctgc ccagggtggc cctgatggac 1020
tggggctgga cgaagccagg gaagaggagg gagacagaga agtggttctg tatggctagg 1080
a 1081

```

```

<210> 3
<211> 3317
<212> DNA
<213> Homo sapiens

```

```

<400> 3
ccccagcgag gctccgggag cccttgcttg cgggggtccg gggactcgag ccggcctccg 60
ccccccggac gcacagccag cgtgggtccc gcgtgcaacg cgagcgccgg ggagtggctc 120
ctgctttgcc cctcgtgggg gccgagccaa gaccagtctg caaactccat cccgccggct 180
ggaagaagtc gcggagccgg caccaaacc gcagcgtctt cccgcgcgga tcccgggact 240
taaaaagccg gggccacccc ggcccaggac gggatgcggg tcgggtccggt gcgtctgcc 300
atgagcggcg cctcgcagcc ccgcggcccc gccctgctct tcccagccac ccgaggcgtc 360
ccggccaaac gcctgctgga cgccgacgac gggcggtctg tgggggcca gtgcccgcgc 420
ctctccgagt gctccagccc cccggactac ctcagcccc ccggctcgcc ctgcagcccg 480
cagccccgcg ctgccgtcc gggggccggc ggaggctccg ggagcgcgcc ggggccagc 540
cgcacgcgag actacctgct gctgccccta gccgagcgcg agcatgtgtc ccggcgctg 600
tgcatccaca ctggacgca gctgcgctgc aaggtgtttc ccattaaaca ctaccaggac 660
aaaatcaggc cttacatcca gctgccatcg cacagcaaca ttactggcat tgtggaagtg 720
atccttgggg aaaccaaggc ctatgtcttc tttgagaagg actttgggga catgcactcc 780
tatgtgcgaa gccggaagag gctgcgggaa gaggaagccg cccggctctt caagcagatt 840
gtctccgccc tcgccactg ccaccagtca gccatcgtgc tgggggacct gaagcttagg 900
aagttcgtct tctccacgga ggagagaacc cagcttagac tagaaagtct agaagacaca 960
cacataatga agggggaaga tgatgctttg tcagacaaac atggctgccc agcctacgtg 1020

```

```

agccctgaga tcctcaacac cactgggacc tactccggaa aggctgcgga cgtttgaggc 1080
ctgggggtga tgctctacac ctttctggtt ggacgatacc ctttccatga ctcagacccc 1140
agtgcctttt tctccaaaat tcggcgtgga cagttctgca ttcctgagca catttcccc 1200
aaagccaggt gcctcattcg cagcctcttg agacgggagc cctccgagag actcactgcc 1260
cccgagatcc tactgcaccc ctggtttgag tccgtcttgg aaccgggta catcgactca 1320
gaaataggaa cttcagacca gattgttcca gagtaccagg aggacagtga cattagttcc 1380
ttcttctgct aatcccaaaa acctcagaaa cctcataatt cttaacacct ggcatattcca 1440
tttctaaaga tggacaggcc ctttggcatg gtaccaacca gataatgact gcatcaggat 1500
gaaagctgct gaactcggca tggcgctcc tcttctctgt tgggatgagt gactttattg 1560
atttgagcag catatgctgt gattggctgc cctgcaaatt tgtttccctt aaggaaccct 1620
caccaactat ctctgctgga tttgggagtt ccgcatcttt tgtggagggc agagtatgga 1680
catcttacac ccggtggta agtgtgtaaat aaacttgagc attcgaatgg gagaaaaagc 1740
aaatcgcaca atgacatatt ttgagtaata accgtatttt tcacaggggtg acaaattggg 1800
ccaataaatc tgccatcttt gaactcatct ttggtggcta gactgctacg gcagcttctc 1860
tgatgggaaa gttccttttt tggtttaaca ctcacccttt ctccacactc acatttacca 1920
atgactctgc tccgtttttg gagcagactg ttttaagttg ctcaggagcc tgatggaacc 1980
atgaaccgag actcttctct gtttctctgc aagacctcat ctgcactaat gccttctccc 2040
tgacctgac acttccccct ttagctataa aagcacttac cagccgaacg tggaacagta 2100
tcacaaaaga ttccatctcc caacgatttc agaactctga gctcagagag actccagatt 2160
ttaaaaaata atttgagtgc ttggaaacta ttagcttttt aagttccttc caaatatggt 2220
agtacctacc ctttactttt tcccaagac catctcaggg tggagcattc tgtctaagag 2280
aagaaagata aggaggctcc caccacctc tcccaagagc agacattaaa catctttgtg 2340
ctttgaagag agtgaatttt ggatagtctt gtgattctca gactaacttc cagaattata 2400
ctttaacccc tcccagatat ggtccgcctt tggcattgtg tgtacatctg cagttttgca 2460
tggtgggttg ttaatatattc aaatgtgtgg tttatgaata cgtctgtata atcggcttct 2520
ggagtgaac agcaaacccc aaatcttcaa agttggaagg aactttaaaa atcatccggt 2580
ccaatctctt tcctctttct gccacctccc aaggcagaaa tccctcttc agcttctttt 2640
gtaggtggga atccagctc tgttagatat gtccagagat ggaaactcac tcccctacaa 2700
aagatggagc ttaatggaga aattgcaact ttcattaaaa aacaaattca gatgaaatat 2760
cagtaactgt cttggacagt gctgaaatca ggtgggtaaa cgggtaaaca aaatatactg 2820
tatthttgaga aatggcacaa aaacaggcag tcacttttaa gggctatgcc taggcaaact 2880

```

```

actaacatgc attgtgagaa tgccgtgtat acctcacgta ctgtgtactt tgtacatata 2940
ttttaccttt tatacctatg ttcgattttg ttttgttttg ttctggcttt gaggcttggt 3000
ttgttgtctg tgtctgtctg aataacctgc gtgtctaaaa ccacgtgaaa tgtgaatgat 3060
tattggcaat attaccttga cagaatcatg ggactttgag aagagggagg acagaggcct 3120
ctgtgcact aacgctctcg tggttgctcg actgttgat ctgtgataca ttatccgact 3180
aaggactctg ggctggcagg gccttctgcc gggaaagcta gaaacactag gttcttctg 3240
tacatacgtg tatatatgtg aacagtgaga tggccgtttc tgacttgtag agaaatttta 3300
ataaacctgg tttcgta 3317

```

```

<210> 4
<211> 1246
<212> DNA
<213> Homo sapiens

```

```

<400> 4
cgcggatccc gggacttaaa aagccggggc caccgccggc caggacggga tgcgggtcgg 60
tccggtgcgc tctgccatga gggcgccctc gcagccccgc ggcccgggcc tgcctctccc 120
agccaccgga ggcgtcccgg ccaaacgcct gctggacgcc gacgacgcgg cggtgtggc 180
ggccaagtgc ccgcgccctc ccgagtgtc cagccccccg gactacctca gcccccccg 240
ctcgccctgc agtccgcagc ccccgccctc cgctccgggg gccggcggag gctccgggag 300
cgcgcggggg ccagccgca tcgccgacta cctgctgtg cccctagccg agcgcgagca 360
tgtgtcccgg gcgctgtgca tccacactgg acgcgagctg cgctgcaagg tgtttcccat 420
taaacactac caggacaaaa tcaggcctta catccagctg ccatcgaca gcaacattac 480
tggcattgtg gaagtgatcc ttggggaaac caaggcctat gtcttctttg agaaggactt 540
tggggacatg cactcctatg tgccaagccg gaagaggctg cgggaagagg aagccgcccg 600
gctcttcaag cagattgtct ccgccgtcgc ccactgccac cagtcagcca tcgtgtggg 660
ggacctgaag cttaggaagt tcgtcttctc cacggaggag agaaccagc ttagactaga 720
aagtctagaa gacacacaca taatgaagg ggaagatgat gctttgtcag acaaacatgg 780
ctgcccagcc tacgtgagcc ctgagatcct caacaccact gggacctact ccggaaaggc 840
tgccggacgtt tggagcctgg ggggtgatgct ctacaccctt ctggttggac gataccctt 900
ccatgactca gacccagtg ccttttctc caaaattcgg cgtggacagt tctgcattcc 960
tgagcacatt tccccaaaag ccagggtgcct cattcgcagc ctcttgagac gggagccctc 1020
cgagagactc actgcccccg agatcctact gcaccctgg tttgagtccg tcttgaacc 1080
cgggtacatc gactcagaaa taggaacttc agaccagatt gttccagagt accaggagga 1140
cagtgcatt agttccttct tctgctaata cccaaaacct cagaaacctc ataattctta 1200

```

acacctggca tttccatttc taaagatgga caggcccttt ggcatg 1246

<210> 5

<211> 4221

<212> DNA

<213> Homo sapiens

<400> 5

gtcggccgtc ccctttaatt tttaaataca cggccccctc ttttctctgg ggggggcaag	60
caagaaatca aagaaggagg agacaagccg tcaattttct ccaaaacaaa ccccaccggg	120
caatttggtc tcggggtagg gggagacggg gtgattgcaa attattccag gacgagatcc	180
agttctccag cgggaaagg gcaaaggaaac gccgcgcgtt ggaaggcca gggtagcgag	240
ctccccctgc agcggccgca ggacccccgc aagctcgtgc cggcgaaatc ggagaccgcc	300
gatctgtcct cgttctctcc tgcacgtctg gctgcattcg gaggaagacc tggggcgcgga	360
gcgagcggcg acagcatgag cctgtgctga cctccgcgcg gcgggcccag cccagggtt	420
tgctgcggta cctgcgcca gccgcgcgcg caactctgtg ccagctttt gcaatctttt	480
gttgcagcgc tgaccgcacc aagttaaag ctcccttgca attttcttt ttttgtttg	540
tttgtttaat ttttgagag ctgcgatct tggaaaagcc tcagacgcca tctacagtta	600
aaacgtaggt aactgccctc tcccgcaccc ccccttaca cggccccac cctttccacc	660
aaaaaaagg ggtgcagcgc ggattctggc tgccgtgctg cgcagccgg tagaccgtg	720
cttgtttcct ttctcttttt gtttggttc taacgcgttg ggactgagtc gccgccgtga	780
gctccccgaa gactgcacaa actaccgcgg gctcctccgc cccgtctgcg attcgggaagc	840
cggcctgggg gtcgcgtcgg gagccctgcg ctgcagctcc gcaccttagc agcccggtga	900
ctcatccaga tccacgccgg ggacacacac acagagtaac taaaagtgcg gcgattctgc	960
acatcgccga ctgctttggg gtaacaaaaa gacccgagtt gcctgccgac cgaggacccc	1020
cgggagccgg gctcggagca gacgaggtat ccggcggcgc ccatttgggg gcttctaact	1080
ctttctccac gcagcccctc ttctgtcccc tcccctctcg ctccctttta aaatcagtgg	1140
caccgaggcg cctgcagccg cactcgccag cgactcatct ctccagcggg tttttttttg	1200
tttgtcgtgt gcgacctca cactcatgaa catacacagg tctaccccca tcacaatagc	1260
gagatatggg agatcgcgga acaaaaccca ggatttcgaa gagttgtcgt ctataaggtc	1320
cgcggagccc agccagagtt tcagcccga cctcggctcc ccgagccgc ccgagactcc	1380
gaacttgtcg cattgcgttt cttgtatcgg gaaatactta ttgttggaac ctctggaggg	1440
agaccacgtt tttcgtgccg tgcattctga cagcggagag gagctggtgt gcaagggtgt	1500
tgatatcagc tgctaccagg aatccctggc accgtgcttt tgctgtctg ctcatagtaa	1560

catcaaccaa atcactgaaa ttatcctggg tgagacccaaa gcctatgtgt tctttgagcg	1620
aagctatggg gacatgcatt ctttcgtccg cacctgcaag aagctgagag aggaggaggc	1680
agccagactg ttctaccaga ttgcctcggc agtggccccc tgccatgacg gggggctggt	1740
gctgccccgac ctcaagctgc ggaaattcat ctttaaggac gaagagagga ctcggtgcaa	1800
gctggaaagc ctggaagacg cctacattct gcggggagat gatgattccc tctccgacaa	1860
gcatggctgc ccggcttacg taagcccaga gatcttgaac accagtggca gctactcggg	1920
caaagcagcc gacgtgtgga gcctgggggt gatgctgtac accatgttgg tggggcggta	1980
ccctttccat gacattgaac ccagctccct cttcagcaag atccggcgtg gccagttcaa	2040
cattccagag actctgtcgc ccaaggccaa gtgcctcatc cgaagcattc tgcgtcggga	2100
gccctcagag cggctgacct cgcaggaaat tctggacct ccttggtttt ctacagattt	2160
tagcgtctcg aattcagcat atggtgctaa ggaagtgtct gaccagctgg tgccggacgt	2220
caacatggaa gagaacttg accctttctt taactgagct catgccccac ggagacttag	2280
caggttccag gagtgagcga gggcagcggg aaggagtctt tccgggggac acgaattgcc	2340
tggctgagta gcaagaaaga cacactctta agtttcttgg ttcagagcag gaaaaccttc	2400
aaggagctga ctgaccacgt agcatggggg caagaggcgt gggatgggga ttggggtgag	2460
atggatggga gcccgtgga gcttgtcttc cctaacatag cctgggagac ccccccttgc	2520
cacttggggc acttccgcct accccacttt tcattttgtt ccaaaatagt tgcagatcct	2580
gacagaatca aaactctctg cctcaaacac acatcctggc atcgactgt tagcatttaa	2640
cttcttgta ggattcaggg aaggaacagt tggccaagaa ttttttttct tttaaacaag	2700
ccaaccacct agctggtaat taatgaggt cacttaaaaa aaaaattcgg tgcacacaga	2760
ctgacatgaa acctgggtgc tacagtaaaa gaaaacaaaa gtccagtttg tgtctcttaa	2820
tcgctcactt caactcattt cttctaaata aactatttaa tatcctggtc aggaaatgac	2880
atgttaaatgc tttgtccct gaagggggaa aaaatctgtc ctttaacaag ctattctgtt	2940
ttgtgtcaat tgggtccgtg gcaaggaagc tattaggaag tcaaacggtc caggatgcat	3000
tacctgctaa tccttaggtt taaaggggga aagaaaaggg aagaagaaag gaaaagagaa	3060
atccaactcc tttttcatgt tttgcttttg aacaatgagg gtttgtgtga caggcattcc	3120
tctttgctga gatgatagca atggcctgag attttagcaa gctcctggag tctgatgctt	3180
ttgcagtact ctgatcgcaa ctaaactttt gtctttgttt tattagaaac tagtgaaaca	3240
aagcaggttg tcccacatgt ataaaataca gggcagctat ttagttttct ttacagagaa	3300
tgatcctttt aaggcttgta aggcctctg gtttggacaa aaacctcag tagagacaag	3360
cggaaggat aattagctga aagctatgat gatataaata aaaacagctc tctatcccaa	3420

```

tacgcacctt tgtattttca agaactcttc tatttattaa ggaaaatgtc acattgtgat 3480
gtattaagcc agtacttcaa ttacgggttg acttgggatg acatattaca tgctgtagtt 3540
aacatttata attctttttc cttgtttgag tatttctgtc tctgaaataa ccttttactt 3600
ggctttttcta gatagcttta tttgatttcg agtggcaaaa tgttttttat tacggctttt 3660
ctattgctgt atgatacaga actcttttgg cataaatatt tgtgttccca gtacctcact 3720
tgttcggatt tgactgcctg tatatgtttt gtgaaatggc cctgtttttg ggtaggtgac 3780
acgtggactc tagtatgtaa atgttacttg aatctgtgct tcataatagt gtgtggcatg 3840
tatgtgcaga ctcttgatg ctttatgcct ggcaccagg agccctgtcc tcacgttccc 3900
aggagggcgg cttcacccctt cgtaaccagg agacaaggcg gccatggatt tgcccttgat 3960
tctattttgc taatggaaga tagaaaggag agaaggtttt tttttttttt taacattctg 4020
aagatggtgc tgtgtcaaga aggacctttt ttttccctc tcccctattt tttaagtacc 4080
ttggaggagg agaggttggg gacatgcatg gtggggatct atggcctctg gtgctttgtc 4140
ctgtatttgg tttaatgttt ttgtccta atcttcaatc aataaaattg tgcgtattta 4200
actaaaaaaa aaaaaaaaaa a 4221

```

```

<210> 6
<211> 4221
<212> DNA
<213> Homo sapiens

```

```

<400> 6
gtcggcgcgc ccctttaatt tttaaataca cggccccctc ttttctctgg ggggggcaag 60
caagaaatca aagaaggagg agacaagccg tcaattttct ccaaaacaaa cccaccggg 120
caatttggtc tcggggtagg gggagacggg gtgattgcaa attattccag gacgagatcc 180
agttctccag cgggaaaggg gcaaaggaa cccgcgcgtt ggaaggcca ggttacgcag 240
ctccccttgc agcgcgcgca ggacccccgc aagctcgtgc cggcgaaatc ggagaccgcc 300
gatctgtcct cgttctctcc tgcacgtctg gctgcattcg gaggaagacc tggggcgcgga 360
gcgagcggcg acagcatgag cctgtgctga cctccgcgcg gcgggcccag cccagggtt 420
tgtcgcggta cctgcgcca gccgcgcgcg caactctgtg cccagctttt gcaatctttt 480
gttgacgcgc tgaccgcacc aagttaaatt ctcccttgca atttttcttt tttttgtttg 540
tttgtttaat ttttgagag ctgcgatct tggaaaagcc tcagacgcca tctacagtta 600
aaacgtagggt aactgcctc tccgcaccc ccccttaca cccccccac ctttccacc 660
aaaaaaaggg ggtgcagcgc ggattctggc tgccgtgcgt cgcagccgg tagaccgtg 720
cttgtttcct ttctcttttt gtttggttc taacgcgttg ggactgagtc gccgccgtga 780
gctccccgaa gactgcacaa actaccgcgc gctcctccgc cccgtctgcg attcgaagc 840

```

cggcctgggg gtcgcgtcgg gagccctgcg ctgcagctcc gcaccttagc agccccgggta	900
ctcatccaga tccacgccgg ggacacacac acagagtaac taaaagtgcg gcgattctgc	960
acatcgccga ctgctttggg gtaacaaaaa gacccgagtt gcctgccgac cgaggacccc	1020
cgggagccgg gctcggagca gacgaggtat ccggcgggcg ccatttgggg gcttctaact	1080
ctttctccac gcagcccctc ttctgtcccc tcccctctcg ctccccttta aaatcagtgg	1140
caccgaggcg cctgcagccg cactcgccag cgactcatct ctccagcggg tttttttttg	1200
tttgtcgtgt gcgatcctca cactcatgaa catacacagg tctaccccca tcacaatagc	1260
gagatatggg agatcgcgga acaaaacca ggatttcgaa gagttgtcgt ctataaggtc	1320
cgcgagagccc agccagagtt tcagcccgaa cctcggtccc ccgagcccgc ccgagactcc	1380
gaacttgtcg cattgcgttt cttgtatcgg gaaatactta ttgttggaac ctctggaggg	1440
agaccacgtt tttcgtgccg tgcattctgca cagcggagag gagctggtgt gcaagggtgt	1500
tgatatcagc tgctaccagg aatccctggc accgtgcttt tgccctgtctg ctcatagtaa	1560
catcaaccaa atcactgaaa ttatcctggg tgagaccaa gcctatgtgt tctttgagcg	1620
aagctatggg gacatgcatt ccttcgtccg cacctgcaag aagctgagag aggaggaggc	1680
agccagactg ttctaccaga ttgcctcggc agtggcccac tgccatgacg gggggctggt	1740
gctgcgggac ctcaagctgc ggaaattcat ctttaaggac gaagagagga ctcggtcaa	1800
gctggaaagc ctggaagacg cctacattct gcggggagat gatgattccc tctccgacaa	1860
gcatggctgc ccggcttacg taagcccaga gatcttgaac accagtggca gctactcggg	1920
caaagcagcc gacgtgtgga gcctgggggt gatgctgtac accatgttgg tggggcggta	1980
ccctttccat gacattgaac ccagctccct cttcagcaag atccggcgtg gccagttcaa	2040
cattccagag actctgtcgc ccaaggccaa gtgcctcatc cgaagcattc tgcgtcggga	2100
gccctcagag cggctgacct cgcaggaaat tctggaccat ccttggtttt ctacagattt	2160
tagcgtctcg aattcagcat atggtgctaa ggaagtgtct gaccagctgg tgccggacgt	2220
caacatggaa gagaacttgg accctttctt taactgagct catgccccac ggagacttag	2280
caggttccag gagtgagcga gggcagcggg aaggagttct tccgggggac acgaattgcc	2340
tggctgagta gcaagaaaga cacactctta agtttcttgg ttcagagcag gaaaaccttc	2400
aaggagctga ctgaccacgt agcatggggg caagaggcgt gggatgggga ttggggtgag	2460
atggatggga gcccgctgga gcttgtcttc cctaacatag cctgggagac cacccttgc	2520
cacttgggac acttccgcct accccacttt tcattttgtt caaaaatagt tgcagatcct	2580
gacagaatca aaactctctg cctcaaacac acatcctggc atcgcaactgt tagcatttaa	2640
cttcttggtta ggattcaggg aaggaacagt tggccaagaa ttttttttct tttaaacaag	2700

```

ccaaccacct agctggtaat taatgaggtt cacttaaaaa aaaaattcgg tgcacacaga 2760
ctgacatgaa acctgggtgc tacagtaaaa gaaaacaaaa gtccagtttg tgtctcttaa 2820
tcgctcactt caactcattt cttctaaata aactatttaa tatcctgggtc aggaaatgac 2880
atgttaatgc tttgctccct gaagggggaa aaaatctgtc ctttaacaag ctattctggt 2940
ttgtgtcaat tgggtccgtg gcaaggaagc tattaggaag tcaaacgggtc caggatgcat 3000
tacctgctaa tccttaggtt taaaggggga aagaaaaggg aagaagaaag gaaaagagaa 3060
atccaactcc tttttcatgt tttgcttttg aacaatgagg gtttgtgtga caggcattcc 3120
tctttgctga gatgatagca atggcctgag attttagcaa gctcctggag tctgatgctt 3180
ttgcagtact ctgatcgcaa ctaaactttt gtctttgttt tattagaaac tagtgaaaca 3240
aagcagggtt tcccacatgt ataaaataca gggcagctat ttagttttct ttacagagaa 3300
tgatcctttt aaggcttgta aggccctctg gtttggacaa aaaccctcag tagagacaag 3360
cggaaggat aattagctga aagctatgat gatataaata aaaacagctc tctatcccaa 3420
tacgcacctt tgtattttca agaactcttc tatttattaa ggaaaatgtc acattgtgat 3480
gtattaagcc agtacttcaa ttacgggttg acttgggatg acatattaca tgctgtagtt 3540
aacatttata attctttttc cttgtttgag tatttctgtc tctgaaataa ctttttactt 3600
ggcttttcta gatagcttta tttgatttcg agtggcaaaa tgttttttat tacggctttt 3660
ctattgctgt atgatacaga actcttttgg cataaatatt tgtgttccca gtacctcact 3720
tgttcggatt tgactgcctg tataatgttt gtgaaatggc cctgtttttg ggtaggtgac 3780
acgtggactc tagtatgtaa atgttacttg aatctgtgct tcataatagt gtgtggcatg 3840
tatgtgcaga ctcttgatg ctttatgcct ggcaccagg agccctgtcc tcacgttccc 3900
aggagggcgg cttcaccctt cgtaaccagg agacaaggcg gccatggatt tgccttgat 3960
tctattttgc taatggaaga tagaaaggag agaaggtttt tttttttttt taacattctg 4020
aagatgggtg tgtgtcaaga aggacctttt ttttccctc tcccctattt tttaagtacc 4080
ttggaggagg agaggttggt gacatgcatg gtggggatct atggcctctg gtgctttgtc 4140
ctgtatttgg tttaatgttt ttgtccta atcttcaatc aataaaattg tgcgtattta 4200
actaaaaaaaa aaaaaaaaaa a 4221

```

<210> 7
 <211> 1038
 <212> DNA
 <213> Homo sapiens

```

<400> 7
actcatgaac atacacaggt ctaccccat cacaatagcg agatatggga gatcgcgga 60

```

```

caaaacccag gatttcgaag agttgtcgtc tataaggtcc ggggagccca gccagagttt 120
cagcccgaac ctgggtccc cgagcccgcc cgagactccg aacttgctgc attgcgtttc 180
ttgtatcggg aaatacttat tgttggaacc tctggaggga gaccacgttt ttcgtgccgt 240
gcatctgcac agcggagagg agctggtgtg caaggtgttt gatatcagct gctaccagga 300
atccctggca ccgtgctttt gcctgtctgc tcatagtaac atcaacaaa tcaactgaaat 360
tatcctgggt gagaccaaag cctatgtgtt ctttgagcga agctatgggg acatgcattc 420
cttcgtccgc acctgcaaga agctgagaga ggaggaggca gccagactgt tctaccagat 480
tgcctcgga gtggcccact gccatgacgg ggggctggtg ctgctgggacc tcaagctgcg 540
gaaattcatc ttaaggacg aagagaggac tcgggtcaag ctggaaagcc tggaagacgc 600
ctacattctg cggggagatg atgattccct ctccgacaag catggctgcc cggcttacgt 660
aagcccagag atcttgaaca ccagtggcag ctactcgggc aaagcagccg acgtgtggag 720
cctgggggtg atgctgtaca ccatgttggg ggggcggtac cctttccatg acattgaacc 780
cagctccctc ttcagcaaga tccggcgtgg ccagttcaac attccagaga ctctgtcgcc 840
caaggccaag tgctcatcc gaagcattct gcgtcgggag cctcagagc ggctgacctc 900
gcaggaaatt ctggaccatc cttggttttc tacagatttt agcgtctcga attcagcata 960
tggtgctaag gaagtgtctg accagctggt gccggacgtc aacatggaag agaacttgga 1020
ccctttcttt aactgagc 1038

```

```

<210> 8
<211> 358
<212> PRT
<213> Homo sapiens

```

```

<400> 8

```

```

Met Arg Ala Thr Pro Leu Ala Ala Pro Ala Gly Ser Leu Ser Arg Lys
1          5          10          15

```

```

Lys Arg Leu Glu Leu Asp Asp Asn Leu Asp Thr Glu Arg Pro Val Gln
20          25          30

```

```

Lys Arg Ala Arg Ser Gly Pro Gln Pro Arg Leu Pro Pro Cys Leu Leu
35          40          45

```

```

Pro Leu Ser Pro Pro Thr Ala Pro Asp Arg Ala Thr Ala Val Ala Thr
50          55          60

```

```

Ala Ser Arg Leu Gly Pro Tyr Val Leu Leu Glu Pro Glu Glu Gly Gly
65          70          75          80

```

Arg Ala Tyr Gln Ala Leu His Cys Pro Thr Gly Thr Glu Tyr Thr Cys
85 90 95

Lys Val Tyr Pro Val Gln Glu Ala Pro Ala Val Leu Glu Pro Tyr Ala
100 105 110

Arg Leu Pro Pro His Lys His Val Ala Arg Pro Thr Glu Val Leu Ala
115 120 125

Gly Thr Gln Leu Leu Tyr Ala Phe Phe Thr Arg Thr His Gly Asp Met
130 135 140

His Ser Leu Val Arg Ser Arg His Arg Ile Pro Glu Pro Glu Ala Ala
145 150 155 160

Val Leu Phe Arg Gln Met Ala Thr Ala Leu Ala His Cys His Gln His
165 170 175

Gly Leu Val Leu Arg Asp Leu Lys Leu Cys Arg Phe Val Phe Ala Asp
180 185 190

Arg Glu Arg Lys Lys Leu Val Leu Glu Asn Leu Glu Asp Ser Cys Val
195 200 205

Leu Thr Gly Pro Asp Asp Ser Leu Trp Asp Lys His Ala Cys Pro Ala
210 215 220

Tyr Val Gly Pro Glu Ile Leu Ser Ser Arg Ala Ser Tyr Ser Gly Lys
225 230 235 240

Ala Ala Asp Val Trp Ser Leu Gly Val Ala Leu Phe Thr Met Leu Ala
245 250 255

Gly His Tyr Pro Phe Gln Asp Ser Glu Pro Val Leu Leu Phe Gly Lys
260 265 270

Ile Arg Arg Gly Ala Tyr Ala Leu Pro Ala Gly Leu Ser Ala Pro Ala
275 280 285

Arg Cys Leu Val Arg Cys Leu Leu Arg Arg Glu Pro Ala Glu Arg Leu
290 295 300

Thr Ala Thr Gly Ile Leu Leu His Pro Trp Leu Arg Gln Asp Pro Met
305 310 315 320

Pro Leu Ala Pro Thr Arg Ser His Leu Trp Glu Ala Ala Gln Val Val
325 330 335

Pro Asp Gly Leu Gly Leu Asp Glu Ala Arg Glu Glu Glu Gly Asp Arg
 340 345 350

Glu Val Val Leu Tyr Gly
 355

<210> 9
 <211> 372
 <212> PRT
 <213> Homo sapiens

<400> 9

Met Arg Val Gly Pro Val Arg Ser Ala Met Ser Gly Ala Ser Gln Pro
 1 5 10 15

Arg Gly Pro Ala Leu Leu Phe Pro Ala Thr Arg Gly Val Pro Ala Lys
 20 25 30

Arg Leu Leu Asp Ala Asp Asp Ala Ala Ala Val Ala Ala Lys Cys Pro
 35 40 45

Arg Leu Ser Glu Cys Ser Ser Pro Pro Asp Tyr Leu Ser Pro Pro Gly
 50 55 60

Ser Pro Cys Ser Pro Gln Pro Pro Pro Ala Ala Pro Gly Ala Gly Gly
 65 70 75 80

Gly Ser Gly Ser Ala Pro Gly Pro Ser Arg Ile Ala Asp Tyr Leu Leu
 85 90 95

Leu Pro Leu Ala Glu Arg Glu His Val Ser Arg Ala Leu Cys Ile His
 100 105 110

Thr Gly Arg Glu Leu Arg Cys Lys Val Phe Pro Ile Lys His Tyr Gln
 115 120 125

Asp Lys Ile Arg Pro Tyr Ile Gln Leu Pro Ser His Ser Asn Ile Thr
 130 135 140

Gly Ile Val Glu Val Ile Leu Gly Glu Thr Lys Ala Tyr Val Phe Phe
 145 150 155 160

Glu Lys Asp Phe Gly Asp Met His Ser Tyr Val Arg Ser Arg Lys Arg
 165 170 175

Leu Arg Glu Glu Glu Ala Ala Arg Leu Phe Lys Gln Ile Val Ser Ala

```

                180                185                190

Val Ala His Cys His Gln Ser Ala Ile Val Leu Gly Asp Leu Lys Leu
    195                200                205

Arg Lys Phe Val Phe Ser Thr Glu Glu Arg Thr Gln Leu Arg Leu Glu
    210                215                220

Ser Leu Glu Asp Thr His Ile Met Lys Gly Glu Asp Asp Ala Leu Ser
    225                230                235                240

Asp Lys His Gly Cys Pro Ala Tyr Val Ser Pro Glu Ile Leu Asn Thr
                245                250                255

Thr Gly Thr Tyr Ser Gly Lys Ala Ala Asp Val Trp Ser Leu Gly Val
    260                265                270

Met Leu Tyr Thr Leu Leu Val Gly Arg Tyr Pro Phe His Asp Ser Asp
    275                280                285

Pro Ser Ala Leu Phe Ser Lys Ile Arg Arg Gly Gln Phe Cys Ile Pro
    290                295                300

Glu His Ile Ser Pro Lys Ala Arg Cys Leu Ile Arg Ser Leu Leu Arg
    305                310                315                320

Arg Glu Pro Ser Glu Arg Leu Thr Ala Pro Glu Ile Leu Leu His Pro
                325                330                335

Trp Phe Glu Ser Val Leu Glu Pro Gly Tyr Ile Asp Ser Glu Ile Gly
    340                345                350

Thr Ser Asp Gln Ile Val Pro Glu Tyr Gln Glu Asp Ser Asp Ile Ser
    355                360                365

Ser Phe Phe Cys
    370

<210> 10
<211> 343
<212> PRT
<213> Homo sapiens

<400> 10

Met Asn Ile His Arg Ser Thr Pro Ile Thr Ile Ala Arg Tyr Gly Arg
 1                5                10                15

```

Ser Arg Asn Lys Thr Gln Asp Phe Glu Glu Leu Ser Ser Ile Arg Ser
 20 25 30

Ala Glu Pro Ser Gln Ser Phe Ser Pro Asn Leu Gly Ser Pro Ser Pro
 35 40 45

Pro Glu Thr Pro Asn Leu Ser His Cys Val Ser Cys Ile Gly Lys Tyr
 50 55 60

Leu Leu Leu Glu Pro Leu Glu Gly Asp His Val Phe Arg Ala Val His
 65 70 75 80

Leu His Ser Gly Glu Glu Leu Val Cys Lys Val Phe Asp Ile Ser Cys
 85 90 95

Tyr Gln Glu Ser Leu Ala Pro Cys Phe Cys Leu Ser Ala His Ser Asn
 100 105 110

Ile Asn Gln Ile Thr Glu Ile Ile Leu Gly Glu Thr Lys Ala Tyr Val
 115 120 125

Phe Phe Glu Arg Ser Tyr Gly Asp Met His Ser Phe Val Arg Thr Cys
 130 135 140

Lys Lys Leu Arg Glu Glu Glu Ala Ala Arg Leu Phe Tyr Gln Ile Ala
 145 150 155 160

Ser Ala Val Ala His Cys His Asp Gly Gly Leu Val Leu Arg Asp Leu
 165 170 175

Lys Leu Arg Lys Phe Ile Phe Lys Asp Glu Glu Arg Thr Arg Val Lys
 180 185 190

Leu Glu Ser Leu Glu Asp Ala Tyr Ile Leu Arg Gly Asp Asp Asp Ser
 195 200 205

Leu Ser Asp Lys His Gly Cys Pro Ala Tyr Val Ser Pro Glu Ile Leu
 210 215 220

Asn Thr Ser Gly Ser Tyr Ser Gly Lys Ala Ala Asp Val Trp Ser Leu
 225 230 235 240

Gly Val Met Leu Tyr Thr Met Leu Val Gly Arg Tyr Pro Phe His Asp
 245 250 255

Ile Glu Pro Ser Ser Leu Phe Ser Lys Ile Arg Arg Gly Gln Phe Asn
 260 265 270

Ile Pro Glu Thr Leu Ser Pro Lys Ala Lys Cys Leu Ile Arg Ser Ile
275 280 285

Leu Arg Arg Glu Pro Ser Glu Arg Leu Thr Ser Gln Glu Ile Leu Asp
290 295 300

His Pro Trp Phe Ser Thr Asp Phe Ser Val Ser Asn Ser Ala Tyr Gly
305 310 315 320

Ala Lys Glu Val Ser Asp Gln Leu Val Pro Asp Val Asn Met Glu Glu
325 330 335

Asn Leu Asp Pro Phe Phe Asn
340